Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Rodolfo Bordoni

Hematology & Oncology Atlanta, GA Medical Doctor

NPI 1215915079 CMS profile 99817

1100 Johnson Ferry Rd Ste 600, Atlanta, GA 30342

Open in the dashboard

General payments

$159,186

136 records reported · program years 2019–2024

Research payments

$657

Paid to them · 2 records reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,859,558 paid to institutions, not to them · program years 2019–2024

Through program year 2024, Rodolfo Bordoni of Atlanta, GA is reported in the CMS Open Payments database as having received $159,186 across 136 general payments and $657 in research payments paid to them. Separately, studies naming them as principal investigator received $3,859,558 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of Hematology & Oncology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $325 2
2023 General $50,872 29
2022 General $21,398 17
2021 General $16,763 21
2020 General $22,804 18
2020 Research $657 2
2019 General $47,024 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodolfo Bordoni
  • Hematology & Oncology median
  • Middle half of Hematology & Oncology
  • National median

In program year 2025, general payments to Rodolfo Bordoni were reported at $0. Among 8,769 Hematology & Oncology profiles paid that year, the median was $683 and the middle half received between $143 and $3,154.

Show as a table
Year Rodolfo Bordoni Hematology & Oncology median Middle half National median
2019 $47,024 $529 $121–$2,516 $163
2020 $22,804 $339 $82–$2,213 $114
2021 $16,763 $263 $49–$1,965 $132
2022 $21,398 $416 $103–$2,395 $149
2023 $50,872 $542 $125–$2,646 $160
2024 $325 $692 $141–$3,008 $164
2025 $0 $683 $143–$3,154 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AstraZeneca Pharmaceuticals LP $75,443 61 payments
  2. Mirati Therapeutics, Inc. $29,910 16 payments
  3. Merck Sharp & Dohme Corporation $12,789 19 payments
  4. Janssen Biotech, Inc. $11,130 12 payments
  5. Genentech USA, Inc. $7,949 6 payments
  6. Takeda Pharmaceuticals U.S.A., Inc. $6,566 6 payments
  7. Genzyme Corporation $3,725 2 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $2,700 2 payments
  9. AstraZeneca UK Limited $2,000 2 payments
  10. MorphoSys, US Inc. $1,770 1 payment
  11. Other $5,204 9 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $105,935 50 payments
  2. Consulting Fee $37,150 23 payments
  3. Travel and Lodging $11,713 20 payments
  4. Food and Beverage $2,814 41 payments
  5. Honoraria $1,500 1 payment
  6. Education $74 1 payment
Products named General payments · program years 2019–2024
  1. TAGRISSO $46,764 33 payments
  2. KRAZATI $29,910 16 payments
  3. IMFINZI Oncology $13,919 14 payments
  4. RYBREVANT $10,696 11 payments
  5. TECENTRIQ $7,949 6 payments
  6. IMFINZI Cardiovascular And Metabolism $7,535 6 payments
  7. KEYTRUDA $7,338 9 payments
  8. EXKIVITY $6,205 3 payments
  9. Alecensa $4,886 3 payments
  10. LIBTAYO $3,725 2 payments
  11. Other $11,043 22 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. F. Hoffmann-La Roche AG $657 2 payments

Records

138 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hematology & Oncology in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record